ArticleBlood2026
STK10 regulates platelet function in arterial thrombosis and thromboinflammation.
Article in Blood, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Research progress on neutrophil extracellular traps in sepsis‑induced coagulopathy (Review).Molecular medicine reports · 2026Review
- STK10 emerges from the platelet kinome shadow.Blood · 2026Article
- Stratified assessment of platelets in sepsis: from dynamic counts to functional phenotypes.Frontiers in immunology · 2026Review
- Illuminating the Co-Phosphoregulatory Network of the Dark Kinase STK10 by Omics Approaches.BioMed research international · 2026Article
Corrections and comments
- Commented on by
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractSerine/threonine kinase 10 (STK10) is a member of the Ste20 family of serine/threonine kinases and regulates lymphocyte adhesion. Quantitative phosphoproteomic assay showed increased STK10 phosphorylation in activated platelets. However, its role in platelet function remains unclear. In our study, we investigated the expression and role of STK10 in platelet function. We first showed STK10 expression in human and mouse platelets. By establishing megakaryocyte/platelet-specific STK10 knockout mice, we found that the deletion of platelet STK10 impaired hemostasis and arterial thrombosis. Consistently, platelet aggregation, α-granule release, αIIbβ3 activation, procoagulant activity, spreading, and clot retraction were all reduced after the deletion of STK10. Quantitative phosphoproteomic assays revealed several dysregulated phosphoproteins, which were enriched in platelet activation and focal adhesion. Using immunoprecipitation coupled to mass spectrometry and protein phosphorylation profiles screening approaches, we identified that STK10 interacts with integrin-linked protein kinase (ILK) and the deletion of STK10 significantly reduced ILK phosphorylation (Ser343). A subsequent in vitro phosphorylation assay demonstrated that STK10 directly phosphorylated ILK at Ser343. In addition, the inhibition of calcium, protein kinase C, or phosphatidylinositol 3-kinase inhibited STK10 phosphorylation in activated platelets. Moreover, the deletion of platelet STK10 reduced platelet-neutrophil interactions, neutrophil accumulation, and neutrophil extracellular trap formation, ameliorated thromboinflammation, and increased the survival of sepsis mice. Furthermore, an increase in the activation of platelet STK10 and ILK was observed in sepsis mice and patients with sepsis. In conclusion, our study identifies a novel regulatory role of STK10 in platelet function, arterial thrombosis, and thromboinflammation, implying that it might be a potential target for the treatment of thrombotic or cardiovascular diseases.
Indexed as
Identifiers
41055696What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.